Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06A in Advanced Esophageal Squamous Cell Carcinoma
jRCT2031220197Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in Phase, Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in Phase and 2 more. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031220197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220197.